|
|
|
|
Clinical Pharmacology at CROI 2010: Advances in Antiretroviral Discovery, Drug Interactions, Compartmental Pen
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Courtney V.Fletcher, Pharm. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198...
|
|
|
Genetic Variability of the HCV NS3 Protease in HIV/HCV Co-infected Patients Treated with HIV Protease Inhibito
-19 SF Marcelle Bottecchia*, A Madejon, M Sanchez-Carrillo, P Labarga, J Garca-Samaniego, and V Soriano Hosp Carlos III, Madrid, Spain Background: Rapid selection of resistance seems to be one of the most challenging aspects in the development of new antivirals...
|
|
|
The Kidney at CROI
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Christina M.Wyatt, MD Assistant Professor, Medicine/ Nephrology Mount Sinai School of Medicine New York, NY Kidney disease and other non-AIDS...
|
|
|
ACTG 5202 Sub-study Finds Lipoatrophy Uncommon, Antiretroviral Drugs Have Varying Effects on Bone and Body Fat
ACTG 5224s, a sub-study of the larger ACTG 5202 trial, looked at 2 types of body composition changes associated with antiretroviral therapy, bone loss and.ACTG 5202 was a randomized Phase 3b clinical trial comparing the effectiveness of commonly used ART...
|
|
|
Onbrez
ACE inhibitor, acetylcholinesterase inhibitor, aciclovir, acne, acute coronary syndrome, acute lymphoblastic leukaemia, ADHD, advanced prostate cancer, advanced renal cell carcinoma, advanced soft tissue sarcoma, adverse reaction, agomelatine, agoraphobia,...
|
|
|
Lotanos Comp
ACE inhibitor, acetylcholinesterase inhibitor, aciclovir, acne, acute coronary syndrome, acute lymphoblastic leukaemia, ADHD, advanced prostate cancer, advanced renal cell carcinoma, advanced soft tissue sarcoma, adverse reaction, agomelatine, agoraphobia,...
|
|
|
Effect of Atazanavir and Atazanavir/Ritonavir on the Pharmacokinetics of the Next Generation Integrase Inhibit
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Reported by Jules Levin 17th CROI Feb 16-19 2010 SF Ivy Song, Julie Borland, Shuguang Chen, Yu Lou, Amanda Peppercorn, Toshihiro Wajima, Sherene Min, Stephen...
|
|
|
Bone & Limb Fat Outcomes in ACTG5202- More Bone Loss With TDF/FTC Than ABC/3TC
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco Mark Mascolini 'All regimens appeared to produce an initial...
|
|
|
Invirase Data Spark Warning: Possible PI Combo Heart Risk
Developers and sellers of protease inhibitors were taking in cautious stride an FDA warning related to preliminary data that suggested Invirase (saquinavir), from Roche Holding Ltd., when combined in the usual way with Abbott's Norvir (ritonavir), another...
|
|
|
Newer HIV Antiretroviral Regimens Produce Few Cases of Lipoatrophy: Presented at CROI
my personal edition> aids and hiv > news E-Mail this DGDispatch to a colleague DGDispatch SAN FRANCISCO -- February 21, 2010 -- Long-term treatment of HIV with regimens anchored by the non-nucleoside reverse transcriptase efavirenz or the protease...
|
|
|
Antiretroviral drugs have variable effects on bones and fat, lipoatrophy uncommon with modern regimens
Different antiretroviral regimen components are linked to varying changes in bone mineral density and body fat, according to a sub-study of the U.S.ACTG 5202 trial reported at the 17th Conference on Retroviruses and Opportunistic Infections (CROI) taking...
|
|
|
EuroSIDA study suggests tenofovir increases risk of chronic kidney disease
An analysis from the large EuroSIDA study found that people who take antiretroviral regimens including tenofovir (Viread) appear to be more likely to develop chronic kidney disease, researchers reported at the 17th Conference on Retroviruses and Opportunistic...
|
|
|
Antiretroviral Risk Factors for Kidney Disease in EuroSIDA: Tenofovir Is Not Alone
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco Mark Mascolini Cumulative exposure to tenofovir, ...
|
|
|
QUAD Four-in-One Pill as Strong as Atripla, But a Kidney Concern Arises
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco Mark Mascolini A once-daily antiretroviral combining the...
|
|
|
Bristol-Myers Squibb Media Statement on ACTG 5202
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 We are pleased with the AIDS Clinical Trials Group (ACTG) data presented today from the Phase IIIb clinical trial ACTG 5202 comparing SUSTIVA (efavirenz),...
|
|
|
Gilead's Single-Tablet "Quad" Regimen For HIV Achieves A High Rate Of Virologic Suppression In Phase II Study
Gilead Sciences, Inc.(Nasdaq:GILD) announced Phase II clinical trial results showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) for...
|
|
|
Gilead's 'Quad' Pill Matches Atripla, New Booster Cobicistat (GS 9350) Looks Good with Atazanavir (Reyataz)
Cal Cohen from the Community Research Initiative of New England reported on 2 s Gilead's 'Quad' Pill Matches Atripla, New Booster Cobicistat (GS 9350) Looks Good with Atazanavir (Reyataz).
|
|
|
Investigative GS-9350 Shows Similar Boosting Efficacy, Safety to Ritonavir: Presented at CROI
The combination tablet, if approved by regulators, would allow patients to take a single, once-daily, integrase inhibitor-based tablet, said Calvin Cohen, MD, Community Research Initiative of New England, Boston, Massachusetts, on February 17.Cohen dubbed...
|
|
|
ACTG 5202: No significant difference in time to failure between Kivexa and Truvada in patients with lower vira
Final results from the ACTG 5202 study were presented at the 17th Conference on Retroviruses and Opportunistic Infections in San Francisco on Wednesday morning.Unlike prior results in patients with viral loads higher than 100,000 copies/ml, in which...
|
|
|
Once-Daily 4-Drug Combination Pill Plus Atazanavir Booster Effective for HIV Patients
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Once-Daily 4-Drug Combination Pill Plus Atazanavir Booster Effective for HIV Patients
_ Once-Daily 4-Drug Combination Pill Plus Atazanavir Booster Effective for HIV Patients.
|
|
|
Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting
Haberl A et al.Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting.
|
|
|
Elvitegravir 'Quad' pill performs well, new booster cobicistat works as well as ritonavir
A new formulation that combines three antiretroviral drugs plus a novel boosting agent in a single once-daily pill was highly effective in a Phase 2 trial of previously untreated participants, researchers reported at the 17th Conference on Retroviruses and...
|
|
|
Gilead s Single-Tablet Quad Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II Study
FOSTER CITY, Calif.-- (BUSINESS WIRE) -- Gilead Sciences, Inc.(Nasdaq:GILD) announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet Quad regimen of elvitegravir, GS 9350 (cobicistat) and Truvada ...
|
|
|
Gilead's Single-Tablet Quad? Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II Study
Second Phase II Study Supports GS 9350 (Cobicistat) as a Boosting Agent FOSTER CITY, Calif.(BUSINESS WIRE) Gilead Sciences, Inc.(Nasdaq:GILD) announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet Quad?
|
